Peregrine Pharmaceuticals (PPHM) Announces Preliminary Results for Phase II Hepatitis Study
Peregrine Pharmaceuticals Inc., a biopharmaceutical company focused on developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today issued an update on its randomized phase II bavituximab study in patients infected with genotype-1 chronic hepatitis C virus (HCV). The goals of the study were to compare the safety profile of bavituximab plus ribavirin with a interferon and ribavirin combination. Preliminary data indicates that the combination of bavituximab and ribavirin appeared safe and well-tolerated in patients who reported fewer side effects than in the interferon-containing arm. The study also indicated that both dose levels of bavituximab with ribavirin…